By Marcus Thornton, Medidata
Clinical trial sites are the backbone of new drug development, but what happens when the relationship frays between sites, clinical research organizations (CROs) and sponsors?
Novel medicines are tested in patients in clinical trials at research sites located at hospitals, academic centers and research institutes. These trials are sponsored by pharmaceutical companies, but often run through an intermediary CRO to manage the trial work. The sites are dependent on the sponsors and CROs to fund the research, but increasingly sites are struggling to receive on-time payments from CROs and sponsors, which threatens to hamper clinical trial work globally.